Brett Sandercock - 03 Nov 2025 Form 4 Insider Report for RESMED INC (RMD)

Reporting relationship: Chief Financial Officer
Issuer ticker: RMD
Reported as of: 03 Nov 2025
Net transaction value: -$539,340
SEC form: 4
Accepted by SEC: 04 Nov 2025, 16:02:37 UTC
Prior SEC filing: 03 Oct 2025
Next SEC filing: 24 Nov 2025
Source filing: View source filing
Reporting owner signature: Brett Sandercock, Chief Financial Officer

Key filing fact

Brett Sandercock filed Form 4 for RESMED INC (RMD) on 04 Nov 2025.

Key facts

This page summarizes Brett Sandercock's Form 4 filing for RESMED INC (RMD).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 04 Nov 2025, 16:02.

Change

Previous filing in this sequence was filed on 03 Oct 2025.
Current net transaction value: -$539,340.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001346064 Primary reporting owner

Sandercock Brett

Relationship: Chief Financial Officer
Address: RESMED INC., 9001 SPECTRUM CENTER BLVD., SAN DIEGO
Signature: Brett Sandercock, Chief Financial Officer
Signature date: 04 Nov 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RMD transaction

ResMed Common Stock

Options Exercise

Transaction value: $203,280
Shares: +2,000
Change %: +2.3%
Price: $101.64
Shares after: 88,745
Date: 03 Nov 2025
Ownership: Direct
Footnotes: F1

RMD transaction

ResMed Common Stock

Sale

Transaction value: $742,620
Shares: -3,000
Change %: -3.4%
Price: $247.54
Shares after: 85,745
Date: 03 Nov 2025
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RMD transaction Derivative

ResMed Common Stock Options

Options Exercise

Transaction value: $0
Shares: -2,000
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 03 Nov 2025
Ownership: Direct
Underlying class: ResMed Common Stock
Underlying amount: 2,000
Exercise price: $101.64
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 2 footnotes

Footnote F1

The transaction was conducted under a Rule 10b5-1 plan adopted February 19, 2025.

Footnote F2

Represents date options first become exercisable. Options vest 1/3 per year.